Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06260059 · ClinicalTrials.gov registry record · Phase 4
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
A Phase 4 study of Heart Failure and Adult Congenital Heart Disease, sponsored by Anita Saraf.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT06260059 is a Phase 4 study of Heart Failure and Adult Congenital Heart Disease that is actively recruiting participants, run by Anita Saraf. The registered enrollment target is 40 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06260059, a Phase 4 study of Heart Failure and Adult Congenital Heart Disease, is actively recruiting participants, sponsored by Anita Saraf.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin 10 MG
Study Locations (3)
Pennsylvania
- Magee Women's Hospital - Pittsburgh
- Presbyterian Hospital - Pittsburgh
- Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06260059
The ClinicalTrials.gov registry entry for NCT06260059 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The listed sponsor is Anita Saraf, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06260059 reports 3 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06260059 about?
NCT06260059 is a clinical study titled "Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease". The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
What is the current status of trial NCT06260059?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2024-09-17. Estimated completion is 2027-06-01.
What conditions does trial NCT06260059 study?
This clinical trial studies the following conditions: Heart Failure, Adult Congenital Heart Disease.
What interventions are being tested in trial NCT06260059?
The interventions under investigation include: Placebo (DRUG), Empagliflozin 10 MG (DRUG).
Who is sponsoring clinical trial NCT06260059?
This trial is sponsored by Anita Saraf, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06260059 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Colchicine in Acutely Decompensated HFREF
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.